{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:39:29Z","timestamp":1772599169825,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Novartis Hellas SACI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-022-02388-8","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T11:03:13Z","timestamp":1678446193000},"page":"2217-2233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod"],"prefix":"10.1007","volume":"40","author":[{"given":"Dimos D.","family":"Mitsikostas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Orologas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efthimios","family":"Dardiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Fakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Triantafyllos","family":"Doskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klimentini","family":"Karageorgiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Maltezou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michail","family":"Vikelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-3301","authenticated-orcid":false,"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"GBD Neurology Collaborators","year":"2019","unstructured":"GBD Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459\u201380.","journal-title":"Lancet Neurol"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175\u201389.","journal-title":"Brain"},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/MRR.0b013e32834ad479","volume":"34","author":"A Goksel Karatepe","year":"2011","unstructured":"Goksel Karatepe A, Kaya T, Gunaydn R, et al. Quality of life in patients with multiple sclerosis: the impact of depression, fatigue, and disability. Int J Rehabil Res. 2011;34:290\u20138.","journal-title":"Int J Rehabil Res"},{"issue":"Suppl 2","key":"2388_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ene.12801","volume":"22","author":"AP Lysandropoulos","year":"2015","unstructured":"Lysandropoulos AP, Havrdova E. \u201cHidden\u201d factors influencing quality of life in patients with multiple sclerosis. Eur J Neurol. 2015;22(Suppl 2):28\u201333.","journal-title":"Eur J Neurol"},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S1474-4422(05)70166-6","volume":"4","author":"AJ Mitchell","year":"2005","unstructured":"Mitchell AJ, Benito-Leon J, Gonzalez JM, et al. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005;4:556\u201366.","journal-title":"Lancet Neurol"},{"issue":"Suppl 5 Improvi","key":"2388_CR6","first-page":"S139","volume":"17","author":"HL Zwibel","year":"2011","unstructured":"Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139\u201345.","journal-title":"Am J Manag Care"},{"key":"2388_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3518","volume":"354","author":"DM Wingerchuk","year":"2016","unstructured":"Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354: i3518.","journal-title":"BMJ"},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","volume":"68","author":"M Gholamzad","year":"2019","unstructured":"Gholamzad M, Ebtekar M, Ardestani MS, et al. A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future. Inflamm Res. 2019;68:25\u201338.","journal-title":"Inflamm Res"},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380-90.e2.","journal-title":"Am J Med"},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387\u2013401.","journal-title":"N Engl J Med"},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS\u00a0II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u201356.","journal-title":"Lancet Neurol"},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","volume":"87","author":"JA Cohen","year":"2016","unstructured":"Cohen JA, Khatri B, Barkhof F, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87:468\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1212\/WNL.0000000000001462","volume":"84","author":"L Kappos","year":"2015","unstructured":"Kappos L, O\u2019Connor P, Radue EW, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582\u201391.","journal-title":"Neurology"},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1185\/03007995.2014.921144","volume":"30","author":"E Baldi","year":"2014","unstructured":"Baldi E, Guareschi A, Vitetta F, et al. Previous treatment influences fingolimod efficacy in relapsing\u2013remitting multiple sclerosis: results from an observational study. Curr Med Res Opin. 2014;30:1849\u201355.","journal-title":"Curr Med Res Opin"},{"key":"2388_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176174","volume":"12","author":"G Izquierdo","year":"2017","unstructured":"Izquierdo G, Damas F, Paramo MD, et al. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study. PLoS\u00a0One. 2017;12:e0176174.","journal-title":"PLoS\u00a0One"},{"key":"2388_CR17","first-page":"205521731880163","volume":"4","author":"G Mazibrada","year":"2018","unstructured":"Mazibrada G, Sharples C, Perfect I. Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): an observational study in the UK. Mult Scler J Exp Transl Clin. 2018;4:2055217318801638.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/ene.13594","volume":"25","author":"C Zecca","year":"2018","unstructured":"Zecca C, Roth S, Findling O, et al. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2018;25:762\u20137.","journal-title":"Eur J Neurol"},{"key":"2388_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/WNF.0000000000000358","volume":"42","author":"L Patrucco","year":"2019","unstructured":"Patrucco L, Cristiano E, S\u00e1nchez F, et al. Real-world effectiveness and safety of fingolimod in patients with relapsing remitting multiple sclerosis: a prospective analysis in Buenos Aires. Argentina Clin Neuropharmacol. 2019;42:163\u20136.","journal-title":"Argentina Clin Neuropharmacol"},{"key":"2388_CR20","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s10072-020-04380-y","volume":"41","author":"G Comi","year":"2020","unstructured":"Comi G, Pozzilli C, Morra VB, et al. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurol Sci. 2020;41:2843\u201351.","journal-title":"Neurol Sci"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/WNF.0000000000000292","volume":"41","author":"AH Ribeiro de Barros","year":"2018","unstructured":"Ribeiro de Barros AH, FiadeiroSequeira JP, Lopes de Sousa AS, et al. Safety and effectiveness of fingolimod in real-world multiple sclerosis Portuguese patients. Clin Neuropharmacol. 2018;41:129\u201335.","journal-title":"Clin Neuropharmacol"},{"key":"2388_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230846","volume":"15","author":"F Barrero","year":"2020","unstructured":"Barrero F, Mallada-Frechin J, Mart\u00ednez-Gin\u00e9s ML, et al. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS\u00a0One. 2020;15:e0230846.","journal-title":"PLoS\u00a0One"},{"key":"2388_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000548","volume":"6","author":"T Ziemssen","year":"2019","unstructured":"Ziemssen T, Lang M, Tackenberg B, et al. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm. 2019;6: e548.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","volume":"14","author":"CJ Nowinski","year":"2017","unstructured":"Nowinski CJ, Miller DM, Cella D. Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials. Neurotherapeutics. 2017;14:934\u201344.","journal-title":"Neurotherapeutics"},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12883-015-0342-0","volume":"15","author":"T Ziemssen","year":"2015","unstructured":"Ziemssen T, Kern R, Cornelissen C. The PANGAEA study design\u2014a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol. 2015;15:93.","journal-title":"BMC Neurol"},{"key":"2388_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.autrev.2017.02.007","volume":"16","author":"T Ziemssen","year":"2017","unstructured":"Ziemssen T, Medin J, Couto CA-M, et al. Multiple sclerosis in the real world: a systematic review of fingolimod as a case study. Autoimmun Rev. 2017;16:355\u201376.","journal-title":"Autoimmun Rev"},{"key":"2388_CR27","unstructured":"Gilenya\u00ae summary of product characteristics. Last updated 04 Feb 2021. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gilenya#product-information-section. Accessed 12 May 2021."},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2147\/PPA.S144021","volume":"12","author":"C M\u00e9ki\u00e8s","year":"2018","unstructured":"M\u00e9ki\u00e8s C, Heinzlef O, Jenny B, et al. Treatment satisfaction and quality of life in patients treated with fingolimod. Patient Prefer Adherence. 2018;12:899\u2013907.","journal-title":"Patient Prefer Adherence"},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"2388_CR30","first-page":"180","volume":"18","author":"J Yfantopoulos","year":"2001","unstructured":"Yfantopoulos J. The Greek version of EuroQol (EQ-5D) instrument. Arch Hell Med. 2001;18:180\u201391.","journal-title":"Arch Hell Med"},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2147\/PPA.S248272","volume":"14","author":"D Schriefer","year":"2020","unstructured":"Schriefer D, Haase R, Kullmann JS, et al. Health-related quality of life and the relationship to treatment satisfaction in patients with multiple sclerosis: insights from a large observational study. Patient Prefer Adherence. 2020;14:869\u201380.","journal-title":"Patient Prefer Adherence"},{"key":"2388_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PPA.S24752","volume":"6","author":"CD Barbosa","year":"2012","unstructured":"Barbosa CD, Balp MM, Kulich K, et al. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39\u201348.","journal-title":"Patient Prefer Adherence"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ane.12033","volume":"126","author":"N Grytten","year":"2012","unstructured":"Grytten N, Aarseth JH, Espeset K, et al. Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis\u2013a multicentre cohort study. Acta Neurol Scand Suppl. 2012;126:51\u20137.","journal-title":"Acta Neurol Scand Suppl"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2377-14-65","volume":"14","author":"A Laroni","year":"2014","unstructured":"Laroni A, Brogi D, Morra VB, et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol. 2014;14:65.","journal-title":"BMC Neurol"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","volume":"3","author":"L Kappos","year":"2014","unstructured":"Kappos L, Cohen J, Collins W, et al. Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings. Mult Scler Relat Disord. 2014;3:494\u2013504.","journal-title":"Mult Scler Relat Disord"},{"key":"2388_CR36","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3109\/00207454.2014.969839","volume":"125","author":"CM Hersh","year":"2015","unstructured":"Hersh CM, Hara-Cleaver C, Rudick RA, et al. Experience with fingolimod in clinical practice. Int J Neurosci. 2015;125:678\u201385.","journal-title":"Int J Neurosci"},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40261-016-0471-2","volume":"37","author":"V Ticha","year":"2017","unstructured":"Ticha V, Kodym R, Pocikova Z, et al. Real-world outcomes in fingolimod-treated patients with multiple sclerosis in the Czech Republic: results from the 12-month GOLEMS study. Clin Drug Investig. 2017;37:175\u201386.","journal-title":"Clin Drug Investig"},{"key":"2388_CR38","doi-asserted-by":"publisher","first-page":"175628641987832","DOI":"10.1177\/1756286419878324","volume":"12","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1756286419878324.","journal-title":"Ther Adv Neurol Disord"},{"key":"2388_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106576","volume":"203","author":"R Alroughania","year":"2021","unstructured":"Alroughania R, Al Kawi Z, Hassan A, et al. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Clin Neurol Neurosurg. 2021;203: 106576.","journal-title":"Clin Neurol Neurosurg"},{"key":"2388_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fneur.2017.00183","volume":"8","author":"T Roux","year":"2017","unstructured":"Roux T, Maillart E, Vidal J-S, et al. Efficacy and safety of fingolimod in daily practice: experience of an academic MS French center. Front Neurol. 2017;8:183.","journal-title":"Front Neurol"},{"key":"2388_CR41","volume":"2015","author":"R Totaro","year":"2015","unstructured":"Totaro R, Di Carmine C, Costantino G, et al. Fingolimod treatment in relapsing-remitting multiple sclerosis patients: a prospective observational multicenter postmarketing study. Mult Scler Int. 2015;2015: 763418.","journal-title":"Mult Scler Int"},{"key":"2388_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1524-4733.2008.00356.x","volume":"11","author":"N Kontodimopoulos","year":"2008","unstructured":"Kontodimopoulos N, Pappa E, Niakas D, et al. Validity of the EuroQoL (EQ-5D) instrument in a Greek general population. Value Health. 2008;11:1162\u20139.","journal-title":"Value Health"},{"key":"2388_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12883-017-0913-3","volume":"17","author":"A Achiron","year":"2017","unstructured":"Achiron A, Aref H, Inshasi J, et al. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. BMC Neurol. 2017;17:150.","journal-title":"BMC Neurol"},{"key":"2388_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/PPA.S41992","volume":"7","author":"KA Hanson","year":"2013","unstructured":"Hanson KA, Agashivala N, Stringer SM, et al. A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod. Patient Prefer Adherence. 2013;7:309\u201318.","journal-title":"Patient Prefer Adherence"},{"key":"2388_CR45","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13104-016-2243-8","volume":"9","author":"P Wicks","year":"2016","unstructured":"Wicks P, Rasouliyan L, Katic B, et al. The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis. BMC Res Notes. 2016;9:434.","journal-title":"BMC Res Notes"},{"key":"2388_CR46","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.2147\/PPA.S166278","volume":"12","author":"K Schreiber","year":"2018","unstructured":"Schreiber K, Kant M, Pfleger C, et al. High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis\u2014results from a 24-month, multicenter, open-label Danish study. Patient Prefer Adherence. 2018;12:1139\u201350.","journal-title":"Patient Prefer Adherence"},{"key":"2388_CR47","first-page":"844","volume":"23","author":"KM Johnson","year":"2017","unstructured":"Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23:844\u201352.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02388-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02388-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:12:05Z","timestamp":1682449925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02388-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02388-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}